Modalis Therapeutics

Modalis Therapeutics

  • Founded: 2016
  • Location: Waltham, MA
  • Employee range: 11 - 50
  • Funding: $15M B Apr 2019
  • Investors: UTokyo Innovation Platform, SBI Investment, Fast Track Initiative, SMBC Venture Capital, Mizuho Capital, CareNet Group


job board

Short description:

Genome Editing Tools

Drug notes:

Contact us to add description:

Long description:

Modalis Therapeutics is a Japan-based biotech company focused on developing gene therapies for rare genetic diseases that often lack effective treatments. They are utilizing a proprietary technology called CRISPR-GNDM® (guide nucleotide-directed modulation), which alters gene expression without permanent changes being made to the DNA sequence. This approach is unlike traditional CRISPR gene editing that cuts DNA. AAV vectors are used to deliver GNDM to the targeted cells. Advantages of this scalable technology include not requiring several doses, having a more sustained effect, and modifying the disease rather than symptom management alone. Indications within their pipeline include muscular, cardiovascular, and CNS disorders. Modalis also has facilities in Cambridge, MA.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy